Tarsus Pharmaceuticals, Inc. Common Stock (TARS) Stock
Key stats
- Market cap
- $3.78B
- Price / Earnings ratio
- -5.2x
- EPS (TTM)
- -$15.18
- Volume
- Loading
- 52-week high
- $91.53
- 52-week low
- $53.89
Source: third-party data provider, as of November 13, 2026
Compare with TARS
Recent news

Tarsus Pharmaceuticals Q3 Earnings Call Highlights
Tarsus Pharmaceuticals Q3 Earnings Call Highlights
TARS

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
TARS

How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
TARS

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
TARS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 59.29
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.70
- MACD histogram
- 0.53
- SMA 50
- $75.02
- Price above SMA 50
- EMA 50
- $72.29
- Price above EMA 50
- SMA 200
- $67.83
- Price above SMA 200
- EMA 200
- $70.92
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

Tarsus Pharmaceuticals Q3 Earnings Call Highlights
Tarsus Pharmaceuticals Q3 Earnings Call Highlights
TARS

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
TARS

How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
How Much Upside is Left in Tarsus Pharmaceuticals (TARS)? Wall Street Analysts Think 30.78%
TARS

Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
Earnings Preview: Tarsus Pharmaceuticals, Inc. (TARS) Q3 Earnings Expected to Decline
TARS

Tarsus Pharmaceuticals Q2 Earnings Call Highlights
Tarsus Pharmaceuticals Q2 Earnings Call Highlights
TARS

Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates
TARS

Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
Tarsus to expand eye disease pipeline with up to $800 million Alkeus acquisition
TARS

Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Tarsus Pharmaceuticals, Inc. (TARS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
TARS

Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline
TARS

All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy
TARS
News tone: automated (AI) classification of the article's content, not a price prediction.
About Tarsus Pharmaceuticals, Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Bobak R. Azamian M.D. | Co-Founder, President, CEO & Chairman | — |
| Mr. Jeffrey S. Farrow CPA | CFO & Chief Strategy Officer | 1962 |
| Dr. Seshadri Neervannan Ph.D. | Chief Operating Officer | 1968 |
| Dr. Bryan Wahl J.D., M.D. | General Counsel & Corporate Secretary | 1978 |
| Mr. David Nakasone | Head of Investor Relations | — |
| Ms. Adrienne Kemp | Vice President of Corporate Communications | — |
| Mr. Matthew Rossen M.B.A. | Vice President of Marketing | 1978 |
| Mr. Scott Youmans | Vice President of Sales | — |
| Ms. Dianne C. Whitfield M.S.W. | Chief Human Resources Officer | 1977 |
| Dr. Elizabeth Yeu-Lin M.D. | Chief Medical Officer | 1978 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 59.29
- MACD 12/26/9
- -0.16
- EMA 9 of MACD
- -0.70
- MACD histogram
- 0.53
- SMA 50
- $75.02
- Price above SMA 50
- EMA 50
- $72.29
- Price above EMA 50
- SMA 200
- $67.83
- Price above SMA 200
- EMA 200
- $70.92
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $97.00
- Average
- $106.80
- High
- $116.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +4.1 | -7.4 | ||||||||||
| 2022 | -17.3 | -14.6 | -11.9 | +6.5 | -1.8 | +7.0 | -0.1 | +0.5 | +11.6 | +8.4 | -6.2 | -13.3 |
| 2023 | +9.3 | -1.0 | -18.0 | +18.7 | +10.1 | +5.9 | +27.2 | -4.2 | +6.7 | -18.3 | +13.9 | +27.7 |
| 2024 | +35.1 | +32.2 | -1.6 | -12.3 | +1.4 | -16.7 | -14.0 | +15.7 | +25.7 | +37.8 | +10.9 | +9.8 |
| 2025 | -2.5 | -17.8 | +20.2 | +6.1 | -14.6 | -7.6 | -2.9 | +43.5 | +1.4 | +20.0 | +14.6 | +2.4 |
| 2026 | -20.1 | +14.5 | -9.4 | -9.4 | -6.6 | +6.8 | -3.0 | +21.1 | +6.2 | -0.8 | +4.7 |



